Introducing InVision Studio, The World’s Most Powerful Screen Design Tool
InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products.
The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow.
With Studio, InVision has developed an end-to-end platform for designing digital experiences. Traditionally, teams have had to cobble their workflow together across a number of disparate tools, many of which were built for earlier generations of graphic and print design. This fragmented workflow slows teams down and prevents them from doing their best work.
Studio starts where the previous generation of screen design tools left off, then adds powerful new dimensions to support today’s modern digital product design workflows in a seamlessly integrated environment:
- Advanced animation: Rapid prototyping and advanced animation turn static screens into live product experiences without requiring a single line of code.
- Responsive design: Studio’s adaptive layout engine enables design across a variety of different devices and orientations, automatically.
- Shared design systems: Shared component libraries are built right into InVision Studio, guaranteeing design teams stay consistent, connected and up to date.
- Connected collaboration: Studio connects seamlessly to InVision’s cloud-based collaboration platform, making it easy to gather feedback and engage stakeholders.
- Extensive app ecosystem: Studio is an open platform allowing users to extend the product experience through an ecosystem of apps and add-ons.
“Since 2011, we’ve been on a mission to help every organization in the world create the digital experiences that shape our lives. The launch of Studio brings us another large step closer to fulfilling that mission, giving our users a complete set of connected tools that drive the digital product design process from start to finish,” said InVision CEO and Co-Founder Clark Valberg. “Every last detail of Studio is the deliberate result of deep insight into how the best digital product teams make the products we love the most. Our goal with this product, and as a company, is to deliver the operating system for building remarkable experiences.”
CUSTOMER QUOTES
“At Airbnb part of the design team’s job is to make our amazing user experience appear obvious,” said Lucas Smith, who oversees Design Tools at Airbnb. “The reality is that behind beautifully designed experiences is a rigorous process. InVision’s existing tools are already a key part of our workflow, and this latest addition will absolutely help us streamline the process further.”
“What makes Studio particularly appealing is that it reduces complexity and makes it incredibly easy to gather feedback from multiple sources, ensuring that we can scale our practice without sacrificing quality,” said Autodesk Senior User Experience Designer Adam Cohen.
InVision Studio is already being used by some of the most forward-thinking design teams, and will be more broadly available starting in January 2018 for both Mac and PC. To see Studio in action and request early access please visit invisionapp.com/studio or attend one of the many upcoming Studio demo events around the globe.
About InVision
InVision is the product design platform powering the world’s best digital experiences. We give product design teams everything they need to effortlessly navigate every stage of the product design process from ideation to developer hand off, all in one place.
Millions of people use InVision to create a streamlined and scalable product design process; rapidly build, test and iterate on prototypes; and collaborate across their entire organization. InVision powers the digital product design process at more than 80 percent of the Fortune 100, and organizations like Airbnb, Amazon, HBO, IBM, Nike, Slack, and Uber use InVision to build digital experiences that customers love.
InVision is a fully distributed company with employees in more than 20 countries around the world. The company has raised more than $135 million in funding from leading investors including Accel, ICONIQ, FirstMark, and Tiger Global. Visit us at InVisionApp.com and InVisionApp.com/blog.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018005490/en/
Contact information
Lindsey Scott
Director of PR and Communications
Press
(at) invisionapp (dot) com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom